NY-AQARA
11.7.2022 09:02:05 CEST | Business Wire | Press release
Aqara, a leading provider of smart home products, announced the wide availability of its Curtain Driver E1, a retrofit solution to automate traditional curtains. Build upon the Zigbee 3.0 protocol with improved reliability, range and energy efficiency, the curtain driver features a battery life of up to 12 months between each charge1 , and connects with other smart home accessories to enable truly automated home experiences2 . The Curtain Driver E1 has been made available on Amazon in both North America (US , Canada ) and Europe (UK , France , Germany , Italy , Spain ), as well as via selective Aqara retailers worldwide3 .
With two variants, namely the Rod Version for rods and the Track Version for U-rails and I-rails, the Aqara Curtain Driver E1 are compatible with a majority of curtains on the market. Thanks to its quiet-yet-powerful motor, heavier curtains of up to 12 kilograms can be pulled. It also features a wide compatibility with third-party ecosystems and voice assistants, including HomeKit/Siri, Alexa, Google Home/ Google Assistant, IFTTT, and the upcoming Matter standard will also be supported after its roll-out4 .
The installation is easy. Just mount the Curtain Driver E1 onto the curtain rod or rail, and no additional tools are required. The retrofit solution requires no new wiring to motorize the curtains, and the 6000mAh battery - which lasts for up to 1-year of use - can be charged via the Type-C port. It’s equipped with a built-in light sensor, allowing the curtain to close by its own when it’s too bright, and vice versa.
Apart from ambient brightness, the Curtain Driver can also be smartly controlled by other conditions, such as pre-set schedules, sunrise/sunset, local weather, and geofencing. For example the curtains open at sunset so that the beautiful view won’t be missed. When connect with other Aqara devices, more possibilities are made possible. Use a Wireless Mini Switch to open, close or stop the curtain by a simple press, or adjust the precise opening by turning the Cube. The Camera Hub G3 even allows the curtain to be controlled with hand gestures.
The Curtain Driver is designed with high flexibility to suit for different scenarios and use cases. Device grouping is supported, so that double sided curtains can be controlled simultaneously. The speed of the curtain driver is adjustable, and the device can be configured to work more quietly in the mornings so that the sleep won’t be interrupted anymore. Moreover, it’s possible to set the duration time for curtain movements, for example to pull the curtain from closed to fully open in an hour, which simulates a natural sunrise.
In celebration of the launch, Aqara now offers a 20% discount for the new device on Amazon. North American customers will enjoy the offer with the promo code USCURTAIN in the US and Canada , while European customers will enjoy it using the promo code CURTAINUKEU in France , Germany , Italy , Spain and the UK . Both codes are valid on July 11th , 2022. And Amazon Prime members will continue to enjoy the discount from July 12th to 13th with no promo code required.
For more details of the Curtain Driver E1, please visit our website .
1. Based on the lab test of two devices on the double panel curtains. The actual battery life may vary, depending on curtain weight, track length, and friction.
2. A Zigbee 3.0 Aqara hub is required.
3. Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real time availability.
4. An OTA update of the compatible Aqara hub is required.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005076/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom